中国经济网北京9月4日讯 截至8月29日收盘，民生加银优选股票以-9.51%的表现垫底今年前8月普 通股票型基金业绩排行榜。 民生加银优选股票前8月业绩表现 | 名称 | 复权单位净 累计单位净值 规模 | | --- | --- | | | 值增长率% 元 亿元 | | 民生加银优选股票 | -9.51 1.7154 0.86 | 来源：同花顺 （责任编辑：郭健东 ） 【免责声明】本文仅代表作者本人观点，与和讯网无关。和讯网站对文中陈述、观点判断保持中立，不对所包含内容 的准确性、可靠性或完整性提供任何明示或暗示的保证。请读者仅作参考，并请自行承担全部责任。邮箱： news_center@staff.hexun.com 从民生加银优选股票二季度前十大重仓股看，该基金持有宁德时代、比亚迪、安井食品、海康威 视、新乳业、三只松鼠、珀莱雅、中宠股份、海澜之家、青岛啤酒。其基金经理刘浩从今年7月才开始 管理公募基金，此前于2018年7月至2020年7月在中国国际金融股份有限公司担任行业研究员。 据悉，该基金成立于2014年12月19日，截至2025年9月3日，其累计收益率为53.71%，累计单位净 值1.7096元 ...

中国经济网北京9月4日讯 截至8月29日收盘，民生加银优选股票以-9.51%的表现垫底今年前8月普 通股票型基金业绩排行榜。 从民生加银优选股票二季度前十大重仓股看，该基金持有宁德时代、比亚迪、安井食品、海康威 视、新乳业、三只松鼠、珀莱雅、中宠股份、海澜之家、青岛啤酒。其基金经理刘浩从今年7月才开始 管理公募基金，此前于2018年7月至2020年7月在中国国际金融股份有限公司担任行业研究员。 据悉，该基金成立于2014年12月19日，截至2025年9月3日，其累计收益率为53.71%，累计单位净 值1.7096元。但在过去的3年里，该基金跌幅却高达36.60%。 | 民生加银优选股票(000884) | | | | --- | --- | --- | | 单位净值(2025-09-03) | 累计净值 | | | 1.3156 -0.44% | 1.7096 | | | 近1月:3.52% | 近3月: -2.65% | 诉6月: -11.70% | | 沂1年:7.05% | 近3年: -36.60% | 成立来:53.71% | 来源：天天基金网 民生加银优选股票前8月业绩表现 | 名称 | 复权单位净 ...

中国经济网北京8月6日讯 （记者 康博） 截至7月31日收盘，在今年前7月的983只（各份额分开计算， 下同）普通股票型基金中，业绩上涨的共有905只，占比高达92%，仅有78只下跌。 华安医药生物股票发起式A、华安医药生物股票发起式C以105.40%、104.88%的涨幅位居榜首。今年二 季报显示，该基金重仓信达生物、石药集团、康方生物、三生制药、泽璟制药、百济神州、云顶新耀、 信立泰（002294）、荣昌生物。从二级市场走势看，前四只个股的年内涨幅均翻倍，其中的三生制药更 是暴涨超过4倍。 资料显示，华安医药生物股票由桑翔宇管理，其曾任鹏华基金管理有限公司助理研究员，2018年9月加 入华安基金，此前历任投资研究部研究员、基金经理助理。 嘉实互融精选由郝淼管理，其原为中国科学院生物化学与分子生物学博士。2010年7月至2011年2月就职 于中国科学院,任助理研究员，从事生物医学领域科研工作；2011年3月至2013年6月就职于平安证券综 合研究所任医药行业研究员；2013年6月加入宝盈基金后任研究员、基金经理助理、专户投资部投资经 理，2021年3月加入嘉实基金，管理公募基金累计时间长达6年。而富国医药创 ...

Core Viewpoint - Minsheng Jia Yin Fund has undergone significant personnel changes, with Zhu Yongming promoted to Deputy General Manager and Ding Hui taking over as Secretary of the Board, both having backgrounds in the major shareholder Minsheng Bank, indicating a continuation of the "Minsheng system" in management [2][5]. Management Changes - Zhu Yongming has effectively taken charge of the investment decision-making committees for equity, fixed income, and asset allocation, becoming the head of investment research despite lacking substantial frontline investment experience [2][4]. - The promotion of Zhu Yongming is seen as a confirmation of his leadership role in investment research, as he had already held key positions in investment decision-making committees prior to his promotion [4][6]. Talent Drain - The fund has experienced a continuous outflow of core investment research talent, starting with the departure of former General Manager Li Caogang, followed by other key personnel, which has negatively impacted fund performance [6][7]. - As of June 9, 2025, several actively managed equity products under Minsheng Jia Yin Fund reported negative returns, highlighting the challenges faced by the investment team [6][7]. Governance Structure Issues - The shareholder structure of Minsheng Jia Yin Fund includes major players like Minsheng Bank and the Royal Bank of Canada, yet this has not translated into sustained growth or stable performance [7][9]. - The fund's management scale has remained below 160 billion since 2022, with significant reductions in the scale of equity and mixed funds, indicating potential governance and operational challenges [7][9]. Market Position and Challenges - Despite a strong background and talent pool, the fund struggles with converting its resources into effective market performance, with a notable concentration of management talent from a single shareholder, which may lead to decision-making biases [9].

中国经济网北京5月23日讯 昨日，深圳商报发布《民生加银基金旗下11只主动权益类基金今年以来负收 益》一文。文中称，民生加银基金旗下主动权益类产品中，有11只今年以来的收益为负，蔡晓旗下有3 只产品成绩不理想。据同花顺数据，民生加银养老服务混合3年又172天的任职回报为-40.98%；民生加 银均衡优选混合A2年又17天的任职回报为-16.89%；民生加银优选股票2年又145天的任职回报 为-9.54%。 其他权益基金经理也有产品成绩不佳。例如，刘霄汉管理民生加银品质消费股票A近4年的回报率 为-43.65%，而同期同类平均收益率为-17.51%；芮定坤管理民生加银品牌蓝筹混合A约3年半的任职回 报为-37.08%。 据悉，上述3只由蔡晓管理的基金均是其任职回报为负的基金。其中，民生加银养老服务混合从2021年 12月1日接手，截至2025年5月22日，其任职回报为-41.31%。 民生加银优选股票则是蔡晓从2022年12月28日管理至今，但任职回报也在这一期间下跌高达20.06%。 A股市场情绪回升牛股频现，政策暖风频吹下反弹行情启动，开户跟进>> | 基金类型 起始时间 截止时间 任职天数 任职回报 2 ...

Group 1 - In April, among 1016 comparable ordinary stock funds, 171 funds saw an increase in performance, 3 remained flat, and 842 experienced a decline [1][2] - The pharmaceutical and biopharmaceutical sectors emerged as the leading sectors, significantly boosting the performance of related thematic funds [1][2] - Notable funds with over 10% growth in April include Bank of China Health Stock A (12.65%), Bank of China Health Stock C (12.61%), and Penghua Pharmaceutical Technology Stock A (11.65%) [1][2] Group 2 - Bank of China Health Stock A and C's top ten holdings include major companies such as Heng Rui Medicine, Xin Nuo Wei, and Bai Li Tian Heng [1] - Penghua Pharmaceutical Technology Stock A and C, managed by veteran Jin Xiaofei, reported increases of 11.65% and 11.62% respectively, with significant holdings in companies like Nuo Cheng Jian Hua and Bai Ji Shen Zhou [2] - Hua An Pharmaceutical Biotechnology Stock A and C also performed well, with monthly growth rates of 10.91% and 10.88% [2] Group 3 - On the downside, nine ordinary stock funds fell over 10% in April, primarily in the consumer electronics and new energy sectors [3][4] - Minsheng Jia Yin Preferred Stock Fund recorded the largest decline at -13.71%, with major holdings including Haier Smart Home and BYD [3] - Other funds like Dongwu Double Triangle Stock A and C also faced significant declines of 11.09% and 11.14% respectively, largely due to their investments in new energy and internet platforms [4] Group 4 - HSBC Jin Trust Low Carbon Pioneer Stock A and C experienced declines of 10.07% and 10.11%, with all top holdings in new energy stocks [4] - The cumulative return of HSBC Jin Trust Low Carbon Pioneer Stock C since its inception is a loss of 58.24% as of April 30 [4] - The management of these funds includes experienced professionals with extensive backgrounds in research and investment [3][4]